- Home
- HOLO vs KLRS Comparison
HOLO vs KLRS Comparison
Compare HOLO & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HOLO | KLRS |
|---|---|---|
| Founded | 2018 | 2019 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.2M | 46.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HOLO | KLRS |
|---|---|---|
| Price | $2.99 | $8.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $20.67 |
| AVG Volume (30 Days) | ★ 592.4K | 170.2K |
| Earning Date | 08-10-2023 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 13.81 | N/A |
| Revenue | ★ $44,840,587.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.21 | ★ N/A |
| Revenue Growth | ★ 37.10 | N/A |
| 52 Week Low | $2.57 | $2.14 |
| 52 Week High | $153.60 | $12.90 |
Technical Indicators
Market Signals| Indicator | HOLO | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 47.32 | 51.92 |
| Support Level | $2.57 | $7.92 |
| Resistance Level | $3.04 | $9.09 |
| Average True Range (ATR) | 0.22 | 0.94 |
| MACD | 0.04 | -0.22 |
| Stochastic Oscillator | 65.41 | 10.47 |
Price Performance
Historical ComparisonAbout HOLO MicroCloud Hologram Inc.
MicroCloud Hologram Inc, through its subsidiaries, is mainly engaged in holographic Technology. It includes Holographic solutions and Holographic technology services. The company also provides holographic digital twin technology services for customers and has built a holographic digital twin technology resource library. Geographically company is operating in single segment, China.
About KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.